Alpha Tau (DRTS) announced the treatment of the first patient in Italy in its feasibility and safety study of intratumoral diffusing alpha-emitter radiation for locally advanced pancreatic cancer. The procedure was performed at the Azienda Ospedaliera Universitaria Integrata di Verona.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DRTS:
- Alpha Tau Treats First Italian Pancreatic Cancer Patient With Alpha DaRT in Verona Study
- Alpha Tau to Present Alpha DaRT–Pembrolizumab Head and Neck Cancer Data at AHNS 2026
- Alpha Tau presents updated results from two clinical trials of Alpha DaRT
- Alpha Tau Reports 100% Local Disease Control in Alpha DaRT Pancreatic Cancer Trials Presented at DDW 2026
- Alpha Tau files $300M mixed securities shelf